Similar articles

• Orgaran in the prevention of deep vein thrombosis in stroke patients.

  Turpie AG. Turpie AG. Haemostasis. 1992;22(2):92-8. doi: 10.1159/000216300. Haemostasis. 1992. PMID: 1379969 Review.
• Orgaran in hip fracture surgery.

  Bergqvist D. Bergqvist D. Haemostasis. 1992;22(2):104-8. doi: 10.1159/000216302. Haemostasis. 1992. PMID: 1379963 Clinical Trial.
• Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators' Group.

  Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, Bucknall T, Stevens J, Porteous F. Gallus A, et al. Thromb Haemost. 1993 Oct 18;70(4):562-7. Thromb Haemost. 1993. PMID: 7509509 Clinical Trial.
• Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine.

  Leyvraz P, Bachmann F, Bohnet J, Breyer HG, Estoppey D, Haas S, Hochreiter J, Jakubek H, Mair J, Sorensen R, et al. Leyvraz P, et al. Br J Surg. 1992 Sep;79(9):911-4. doi: 10.1002/bjs.1800790919. Br J Surg. 1992. PMID: 1422754 Clinical Trial.
• Clinical use of heparin fractions, fragments, and heparinoids.

  Messmore HL Jr. Messmore HL Jr. Semin Thromb Hemost. 1985 Apr;11(2):208-12. doi: 10.1055/s-2007-1004376. Semin Thromb Hemost. 1985. PMID: 2412297 Review. No abstract available.